Retatrutide
The "Triple G" peptide currently in final testing, promising even greater weight loss than its predecessors.
What it is
Retatrutide is the latest evolution in metabolic peptides, currently undergoing Phase 3 clinical trials as of early 2026. It is a "triple agonist," meaning it targets three different hormone receptors: GLP-1, GIP, and Glucagon. While Semaglutide and Tirzepatide focus on the first two, the addition of the Glucagon receptor is what sets Retatrutide apart.
Developed by Eli Lilly, it is often referred to in research circles as the "Triple G." It is designed to maximize energy expenditure and fat burning while maintaining the appetite-suppressing effects of its predecessors.
What it does
The unique "triple-action" approach is designed to attack obesity from every angle. The GLP-1 and GIP components handle appetite and insulin, while the Glucagon component tells the liver to burn more energy and increases the body's resting metabolic rate.
Researchers believe this combination could be particularly effective for people with fatty liver disease (MASH), as glucagon plays a direct role in liver fat metabolism. Users in research settings are investigating it for its potential to surpass the weight-loss results of Tirzepatide.
What the evidence says
In its Phase 2 clinical trials, Retatrutide showed staggering results: participants lost an average of 24% of their body weight over 48 weeks. This is the highest weight-loss percentage ever recorded for a medication. Importantly, 100% of participants on the highest dose lost at least 5% of their weight.
While these results are promising, the drug is not yet FDA-approved. Phase 3 trials are expected to wrap up in 2026, with an NDA filing expected by late 2026. Phase 3 readouts will provide more definitive data on safety, particularly regarding the dose-dependent increase in heart rate observed in Phase 2.
What it costs
Because it is still in the "investigational" phase, Retatrutide is not legally available for purchase for human use in the US. In the gray-market research chemical space, it is extremely expensive due to its novelty and complexity to manufacture, often costing $150 to $300 per 5mg vial. The FDA has issued explicit warning letters against unapproved/compounded versions.
Side effects and risks
The side effect profile appears similar to Tirzepatide—mostly gastrointestinal—but with a notable addition: a dose-dependent increase in heart rate that peaked around 24 weeks in Phase 2. Researchers are monitoring this closely to ensure it doesn't lead to cardiovascular issues over long-term use. Users in research circles have also reported significant chills and skin sensitivity, though these reports remain secondary to the primary GI concerns.
Where users source it
Currently, Retatrutide should only be accessed through official clinical trials. We warn against "early access" through gray-market research sites: the peptide is difficult to synthesize correctly, the long-term safety profile is not yet established, and the FDA has issued explicit prohibitions on 503A/503B compounding of Retatrutide.
Sources
- Jastreboff AM, et al. (2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. PMID 37366315
- Mueller TD, et al. (2023). "Retatrutide: a triple G agonist for the treatment of obesity." Nature Reviews Endocrinology.
- Truth in Peptides. (April 2026). "Retatrutide FDA Status — 2026."
- TODAY. (January 2026). "New weight-loss drugs promise 'profound' results."
A breakthrough GLP-1 medication that has transformed how we approach weight management and metabolic health.
Often called a "twincretin," this dual-action peptide is currently the most potent FDA-approved weight-loss tool.
Often called the "Body Protection Compound," this gastric-derived peptide is a staple in recovery research circles.